Replies to post #163240 on Biotech Values

[mcbio]

Neither could I, which is why I asked. The (presumed) non-disclosure of GILD’s final null-responder results from the ELECTRON study suggests that one or more of the 9 patients in this cohort eventually relapsed.

Thanks for this discussion. This only strengthens my conviction to not bail on Medivir here and continue to hold, for better or worse.